Can-Fite BioPharma Ltd. (CANF) Earnings History
Annual and quarterly earnings data from 2011 to 2024
Loading earnings history...
CANF EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
CANF Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 100.0% | -1206.2% | -1169.1% |
| 2023 | 100.0% | -1103.0% | -1027.5% |
| 2022 | 100.0% | -1246.4% | -1255.9% |
| 2021 | 100.0% | -1505.5% | -1476.6% |
| 2020 | 100.0% | -1853.1% | -1892.9% |
Download Data
Export CANF earnings history in CSV or JSON format
Free sign-in required to download data
Can-Fite BioPharma Ltd. (CANF) Earnings Overview
As of May 8, 2026, Can-Fite BioPharma Ltd. (CANF) reported trailing twelve-month net income of -$9M, reflecting +40.0% year-over-year growth. The company earned $-0.77 per diluted share over the past four quarters, with a net profit margin of -1169.1%.
Looking at the long-term picture, CANF's historical earnings data spans multiple years. The company achieved its highest annual net income of -$5M in fiscal 2015.
Can-Fite BioPharma Ltd. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including RCUS (-$369M net income, -142.9% margin), PRAX (-$327M net income), ACAD ($376M net income, 36.5% margin), CANF has room to improve margins relative to the peer group. Compare CANF vs RCUS →
CANF Earnings vs Peers
Earnings metrics vs comparable public companies
CANF Historical Earnings Data (2011–2024)
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$8M | -3.2% | -$8M | $-1.08 | -1169.1% | -1206.2% |
| 2023 | -$8M | +25.0% | -$8M | $-1.80 | -1027.5% | -1103.0% |
| 2022 | -$10M | +19.2% | -$10M | $-3.75 | -1255.9% | -1246.4% |
| 2021 | -$13M | +12.8% | -$13M | $-8.25 | -1476.6% | -1505.5% |
| 2020 | -$14M | -14.4% | -$14M | $-12.69 | -1892.9% | -1853.1% |
| 2019 | -$13M | -92.1% | -$12M | $-45.00 | -621.3% | -590.9% |
| 2018 | -$7M | -32.2% | -$5M | $-51.00 | -172.0% | -141.7% |
| 2017 | -$5M | +28.0% | -$7M | $-57.00 | -588.2% | -873.1% |
| 2016 | -$7M | -43.8% | -$9M | $-90.00 | -4069.3% | -5093.7% |
| 2015 | -$5M | +21.4% | -$6M | $-81.00 | -2912.3% | -3894.6% |
See CANF's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CANF Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CANF vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCANF — Frequently Asked Questions
Quick answers to the most common questions about buying CANF stock.
Is CANF growing earnings?
CANF EPS is $-0.77, with earnings growth accelerating to +40.0%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-9M.
What are CANF's profit margins?
Can-Fite BioPharma Ltd. net margin is -1169.1%, with operating margin at -1206.2%. Below-average margins reflect competitive or cost pressures.
How consistent are CANF's earnings?
CANF earnings data spans 2011-2024. The accelerating earnings trend is +40.0% YoY. Historical data enables comparison across business cycles.